Neurocrine's NBI-1065845 Shows Promise as Adjunctive Treatment for Major Depressive Disorder
A study is underway to assess the efficacy and safety of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder.
Asset / Drug
Drug and asset intelligence for Neurocrine with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.